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ABSTRACT A marked decrease in the type I cAMP-
dependent protein kinase regulatory subunit (RIe) and an
increase in the type II protein kinase regulatory subunit (Rllp)
correlate with growth inhibition and differentiation induced in
a variety of types ofhuman cancer cells, in vitro and in vivo, by
site-selective cAMP analogs. To directly determine whether
RI,, is a growth-inducing protein essential for neoplastic cell
growth, human HL-60 promyelocytic leukemia cells were
exposed to 21-mer RIa antisense oligodeoxynucleotide, and the
effects on cell replication and differentiation were examined.
The RI, antisense oligomer brought about growth inhibition
and monocytic differentiation, bypassing the effects of an
exogenous cAMP analog. These effects of RI. antisense oli-
godeoxynucleotide correlated with a decrease in RI. receptor
and an increase in Rllp receptor level. The growth inhibition
and differentiation were abolished, however, when these cells
were exposed simultaneously to both RI. and RUp antisense
oligodeoxynucleotides. The RIIp antisense oligodeoxynucleo-
tide alone has been previously shown to specifically block the
differentiation inducible by cAMP analogs. These results pro-
vide direct evidence that RI. cAMP receptor plays a critical
role in neoplastic cell growth and that cAMP receptor isoforms
display specific roles in cAMP regulation of cell growth and
differentiation.
cAMP-dependent protein kinase is composed of two genet-
ically distinct subunits, catalytic (C) and regulatory (R). The
activating ligand cAMP, which binds to the R, induces
conformational changes and dissociates holoenzyme R2C2
into an R2 (cAMP)4 dimer and two free C that are catalytically
active (1, 2). There are two different classes of cAMP-
dependent protein kinase designated as type I and type II,
which contain distinct R, RI and RII, respectively, but share
a common C (3, 4). Four different regulatory subunits [RI,
(RI) (5), RIp (6), RIIa,, (RI154) (7), and R13 (RI151) (8)] havebeen identified at the gene/mRNA level. Two distinct C [C,
(9) and Cp (10, 11)] have also been identified; however,
preferential coexpression of either one of these C with either
the type I or type II protein kinase R has not been found (11).
It has been shown that the ratio of cAMP-dependent
protein kinases type I and type II varies among tissues and
that an increased expression of protein kinase type I or RI
correlates with active cell growth, cell transformation, or
early stages of differentiation (12).
We hypothesized that RI is an ontogenic growth-inducing
protein, and its constitutive expression disrupts normal on-
togenic processes, resulting in a pathogenic outgrowth, such
as malignancy. To directly determine whether RI has a role
in neoplastic cell growth, at least in vitro, we used the
antisense strategy (13). We used 21-mer synthetic oligode-
oxynucleotides complementary to either the sense or an-
tisense strands of the human RIa (14) mRNA transcript
starting from the first codon (15-17). We then exposed human
HL-60 leukemia cells to these oligodeoxynucleotides and
examined the effects of this treatment on cell proliferation
and differentiation. As additional controls, we also synthe-
sized RIIa (18) and RIIp (19) antisense and a random-
sequence oligodeoxynucleotide of identical size.
MATERIALS AND METHODS
Oligodeoxynucleotides. The 21-mer oligodeoxynucleotides
used in the present studies were synthesized at Midland
Certified Reagent (Midland, TX) and had the following se-
quences: human RIa (14) antisense, 5'-GGC-GGT-ACT-
GCC-AGA-CTC-CAT-3'; human RII, (19) antisense, 5'-
CGC-CGG-GAT-CTC-GAT-GCT-CAT-3'; human RIla (18)
antisense, 5'-CGG-GAT-CTG-GAT-GTG-GCT-CAT-3'; and
the random-sequence oligodeoxynucleotide was made of a
mixture of all four nucleotides at every position.
Cel Growth Experiment. Cells grown in suspension culture in
RPMI 1640 medium/l0o fetal bovine serum/penicillin at 50
units/ml/streptomycin at 500 ,ug/ml/1 mM glutamine (GIBCO)
were seeded at 5 x 105 cells per dish. Oligodeoxynucleotides
were added after seeding and every 48 hr thereafter. Cell counts
were performed on a Coulter Counter. Cells unexposed or
exposed to oligodeoxynucleotides for 4 days were reseeded
(day 0) at 5 x 105 cells per dish, and cells preexposed to the
oligodeoxynucleotide were further treated with the oligomer at
day 0 and day 2. cAMP analogs (provided by R. K. Robins,
Nucleic Acid Research Institute, Costa Mesa, CA) or phorbol
12-myristate 13-acetate (PMA) were added one time at day 0.
Cell counts were performed on day 4.
Immunoprecipitation of RIa and Rllp cAMP Receptor Pro-
teins After Photoaflnmity Labeling with 8-Azidoadenosine 3',5'-
Cyclic [32P]Monophosphate ([32P18-N3-cAMP). Cell extracts
were prepared at 0-40C. The cell pellets (2 x 106 cells), after
two washes with phosphate-buffered saline, were suspended
in 0.5 ml of buffer Ten (0.1 M NaCl/5 mM MgCl2/1% Nonidet
P40/0.5% sodium deoxycholate/bovine aprotinin at 2 kal-
likrein inhibitor units per ml/20 mM Tris-HCl, pH 7.4) con-
taining proteolysis inhibitors (17), Vortex-mixed, passed
through a 22-gauge needle 10 times, allowed to stand for 30 min
at 40C, and centrifuged at 750 x g for 20 min; the resulting
supernatants were used as cell lysates. The photoactivated
incorporation of [32P]8-N3-cAMP (60.0 Ci/mmol; 1 Ci = 37
GBq) and the immunoprecipitation using the anti-RI,,, or anti-
RII,6 antiserum (provided by S. 0. D0skeland, University of
Abbreviations: C, catalytic subunit(s); R, regulatory subunit(s);
PMA, phorbol 12-myristate 13-acetate; RI and RII, type I and type
lI R, respectively; [32P]8-N3-cAMP, 8-azidoadenosine 3',5'-cyclic[32P]monophosphate; 8-Cl-cAMP, 8-chloroadenosine 3',5'-cyclic
monophosphate.
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Bergen, Bergen, Norway) and protein A-Sepharose and SDS/
PAGE of solubilized antigen-antibody complex followed the
method described (17, 20).
cAMP-Dependent Protein Kinase Assays. After two washes
with Dulbecco's phosphate-buffered saline, cell pellets (2 x
106 cells) were lysed in 0.5 ml of 20 mM Tris, pH 7.5/0.1 mM
sodium EDTA/1 mM dithiothreitol/0.1 mM pepstatin/0.1
mM antipain/0.1 mM chymostatin/0.2 mM leupeptin/
aprotinin at 0.4 mg/ml/soybean trypsin inhibitor at 0.5 mg/ml,
using 100 strokes of a Dounce homogenizer. After centrifu-
gation (Eppendorf 5412) for 5 min, the supernatants were
adjusted to 0.7 mg of protein per ml and assayed (21)
immediately. Assays (40,ul, total volume) were performed for
10 min at 30'C and contained 200 ,4M ATP, 2.7 x 106 cpm
[_y-32P]ATP, 20 mM MgCl2, 100,/M kemptide (Sigma K-1127)
(22), 40 mM Tris (pH 7.5), ± 100 ,uM protein kinase inhibitor
(Sigma P-3294) (23), ± 8 ,uM cAMP and 7 ,ug of cell extract.
The phosphorylation of kemptide was determined by spotting
20 ,l of incubation mixture on phosphocellulose filters
(Whatman P81) and washing them in phosphoric acid as
described (24). Radioactivity was measured by liquid scin-
tillation with Econofluor-2 (NEN Research Products NEF-
969).
Isolation of Total RNA and Northern (RNA) Blot Analysis.
The cells (108 washed twice with phosphate-buffered saline)
were lysed in 4.2 M guanidine isothiocyanate/25 mM sodium
citrate, pH 7.0/0.5% sarcosyl (N-lauroylsarcosine Na+)/0.1
M 2-mercaptoethanol, and the lysates were homogenized;
total cellular RNA was sedimented through a CsCl cushion
(5.7 M CsCl/10 mM EDTA) as described by Chirgwin et al.
(25). Total cellular RNA in 20 mM 3-(N-morpholine)propane-
sulfonic acid, pH 7.0/50% (vol/vol) formamide/6% (vol/vol)
formaldehyde was denatured at 65°C for 10 min and electro-
phoresed through a denaturing 1.2% agarose/2.2 M formal-
dehyde gel. The gels were then transferred to Biotrans nylon
membranes (ICN) by the method ofThomas (26) and hybrid-
ized to the following two 32P-labeled nick-translated cDNA
probes: 1.5-kilobase (kb) cDNA clone containing the entire
coding region for the human cAMP-dependent protein kinase
type I R, RIa (14) (provided by T. Jahnsen, Institute of
Pathology, Rikshospitalet, Oslo, Norway) and human 8 actin
(Oncor p7000 1 actin).
RESULTS AND DISCUSSION
The RIa antisense oligodeoxynucleotide at 15 ,uM concen-
tration (17) had immediate effects on the rate of proliferation
ofHL-60 cells. By 4-5 days in culture, cells unexposed to RIa
antisense oligomer demonstrated an exponential rate of
growth, whereas cells exposed to the RIa antisense oligomer
exhibited a reduced growth rate and eventually stopped
replicating (Fig. 1A). This inhibitory effect on cell prolifera-
tion persisted throughout the culture period. The growth
inhibition was not due to cell killing; cells were >90% viable
after exposure to RIa antisense oligomer (15 ,uM) for 7 days
as assessed by flow cytometry by using forward and side
scatter. RIa, sense, Rlla, RIIf3 antisense, or a random-
sequence oligodeoxynucleotide had no such growth inhibi-
tory effect.
Cells unexposed or exposed to RIa antisense oligodeoxy-
nucleotide for 4 days in culture were reseeded and examined
for their response to treatment with cAMP analogs or PMA.
In cells unexposed to RIa antisense oligodeoxynucleotide,
8-chloradenosine 3',5'-cyclic monophosphate (8-Cl-cAMP)
(10 ,uM) produced 60% growth inhibition, and 80% growth
inhibition was achieved by 8-Cl-cAMP (5 ,uM) plus N6-
benzyl-cAMP (5 ,uM) (Fig. 1B) (27); PMA (10-8 M) exhibited
60% growth inhibition (Fig. 1B). In contrast, cells exposed to
RIa antisense oligodeoxynucleotide exhibited retarded
growth (=25% the rate of growth of cells unexposed to the
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FIG. 1. Effect of RIa antisense oligodeoxynucleotide on the basal
rate of growth of HL-60 leukemic cells (A) and the growth of these
cells when treated with cAMP analogs or PMA (B). (A) Cells were
grown without (o) or with (e) RI,, antisense oligodeoxynucleotide (15
AM). At indicated times, cell counts in duplicate were performed.
Data represent the average values ± SDs offour experiments. (B) On
day 4 of experiment A, cells exposed or unexposed to Rla antisense
oligodeoxynucleotide were reseeded (day 0) at 5 x 105 cells per dish,
and cells preexposed to RIa antisense oligodeoxynucleotide were
further treated with the oligomer at day 0 and 2. cAMP analogs and
PMA were added once at day 0. Cells were counted on a Coulter
Counter on day 4. 8-Cl, 8-Cl-cAMP (10 AM); 8-Cl + N6-B, 8-Cl-
cAMP (5 ,M) + N6-benzyl-cAMP (5 ,uM); PMA (10-8 M). Data
represent the average values ± SDs of four experiments.
RIa antisense oligomer), and neither cAMP analogs nor PMA
further retarded growth (Fig. 1B).
HL-60 cells undergo a monocytic differentiation upon
treatment with site-selective cAMP analogs (27). Cells either
unexposed or exposed to RIa antisense oligodeoxynucleotide
were examined for their morphology before and after treat-
ment with cAMP analogs. As shown in Fig. 2, in cells
unexposed to RIa antisense oligomer, 8-Cl-cAMP plus N6-
benzyl-cAMP induced a monocytic morphologic change
characterized by a decrease in nuclear-to-cytoplasm ratio,
abundant ruffled and vacuolated cytoplasm, and loss of
nucleoli (27). Strikingly, the same morphologic change was
induced when cells were exposed to RIa antisense oligode-
oxynucleotide (Fig. 2). Moreover, the morphologic changes
induced by RIa antisense oligomer were indistinguishable
from that induced by PMA (Fig. 2).
To provide more evidence that the growth inhibition and
monocytic differentiation induced in HL-60 cells exposed to
the RI, antisense oligodeoxynucleotide were due to an in-
tracellular effect of the oligomer, we determined the RIa
mRNA level. As shown in Fig. 3, 3.0-kb RI, mRNA (14) was
virtually undetectable in cells exposed for 8 hr to RIa an-
tisense oligodeoxynucleotide (Fig. 3B, lane 2), and the de-
crease in RIa mRNA was not due to a lower amount of total
RNA as shown by the ethidium bromide staining (compare
lane 2 with lane 1 of Fig. 3A). Conversely, an enhanced level
of actin mRNA was detected in cells exposed to RI, antisense
oligomer (Fig. 3B). Whether the increase in actin mRNA level
represents changes in cytoskeletal structure is not known.
We next determined the levels of cAMP receptor proteins
in these cells by immunoprecipitation with anti-RIa and
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* FIG. 2. Effect of RI,, antisense oh-
godeoxynucleotide on the morphologic
transformation of HL-60 cells. Cells ei-
ther exposed or unexposed to RI<, an-
tisense oligodeoxynucleotide were
treated with cAMP analogs or PMA as
described in Fig. 1B. On day 4 (see Fig.
1B), cells were washed twice in Dulbec-
co's phosphate-buffered saline and were
pelleted onto a glass slide by cytocentri-
fuge. The resulting cytopreparations
were fixed and stained by Wright's stain.
(x120.)
anti-RII# antisera (17, 20) after photoaffinity labeling of these
receptor proteins with [32P]8-N3-cAMP. In control cells,
treatment with 8-Cl-cAMP plus NM-benzyl-cAMP reduced
RIa -70% and increased Rh1p 3-fold, resulting in a 10-fold
increase in the ratio of RII13/RIh (Fig. 4) (28). Exposure of
these cells to RIa antisense oligodeoxynucleotide for 4 days
brought about marked changes in both RIa and Rh11 levels; an
80% reduction in RIa with a 5-fold increase in Rh11 resulted
in a 25-fold increase in the ratio of RII1/Rla compared with
that in control cells (Fig. 4). Because growth inhibition and
differentiation were appreciable after 3- to 4-day exposure to
RIa antisense oligomer, the changing levels of RIa and RIIS
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FIG. 3. Decreased RI, mRNA expression in HL-60 leukemic
cells exposed to RIa antisense oligodeoxynucleotide. Cells were
either exposed or unexposed to RI, antisense oligodeoxynucleotide
(15 AM) for 8 hr. Isolation of total RNA and Northern blot analysis
followed the described methods. (A) Ethidium bromide staining of
RNA. Lanes: M, markers of ribosomal RNAs; 1, cells unexposed to
RI, antisense oligomer; 2, cells exposed to RI,, antisense oligomer.
(B) Northern blot analysis; the same nitrocellulose filter was hybrid-
ized to both RIa and actin probes in sequential manner. Lanes: 1,
cells unexposed to RIa antisense oligomer; 2, cells exposed to RIa
antisense oligomer.
proteins appear an early event necessary for commitment to
differentiation.
Data in Fig. 4 showed that suppression of RIa by the
antisense oligodeoxynucleotide brought about a compensa-
tory increase in RMgS level. Such coordinated expression ofRI
and RII without changes in the amount of C has been shown
(29, 30). The increase in Rh13 may be responsible for the
differentiation induced in these cells after exposure to RIa
antisense oligodeoxynucleotide. The increase in RIIh mRNA
or Rh13 protein level has been correlated with cAMP analog-
induced differentiation in K-562 chronic myelocytic leukemic
cells (31) and in erythroid differentiation of Friend erythro-
cytic leukemic cells (32). In a recent report (17), we have
provided direct evidence that RIIh is essential for the cAMP-
induced differentiation in HL-60 cells. HL-60 cells that were
exposed to Rh13 antisense oligodeoxynucleotide became re-
fractory to treatment with cAMP analogs and continued to
grow.
The essential role of RII3 in differentiation of HL-60 cells
was further demonstrated when these cells were exposed to
both RI, and Rh11 antisense oligodeoxynucleotides simulta-
neously. As shown in Table 1, RI,, antisense oligodeoxynu-
cleotide markedly increased the expression of monocytic
surface antigens [Leu 15 (33) and Leu M3 (34)] and decreased
markers related to the immature myelogenous cells [My9 (35,
36)]. These changes in surface marker expression were
abolished when cells were exposed simultaneously to both
RIa and RII3 antisense oligodeoxynucleotides (Table 1). RIIa
cAMP receptor was not detected in HL-60 cells (37), and RIa
antisense oligodeoxynucleotide showed no interference with
the effects of RI,,, antisense oligomer (Table 1).
Cells exposed to both RI, and Rh13 antisense oligodeoxy-
nucleotides were neither growth inhibited nor differentiated
regardless of cAMP analog treatment. We interpret these
results to reflect the blockage of cAMP-dependent growth
regulatory pathway. Cells under these conditions are no
longer cAMP-dependent but survive and proliferate probably
through an alternate pathway. Thus, suppression of both RIa
.s
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FIG. 4. Effect of RI, antisense oligodeoxynucleotide on the basal
and induced levels of RIa and RIH, cAMP receptor proteins in HL-60
leukemic cells. Cells were either exposed to RIa antisense oligode-
oxynucleotide (15 MM) or treated with cAMP analogs as described in
Fig. 1. Preparation of cell extracts, the photoactivated incorporation
of [32P]8-N3-cAMP and immunoprecipitation with the anti-RIa or
anti-RIIp antiserum and protein A-Sepharose, and SDS/PAGE of
solubilized antigen-antibody complex followed the methods de-
scribed. Preimmune serum controls were carried out simultaneously
and showed no immunoprecipitated band. Lanes: M, 14C-labeled
marker proteins of known Mr; RIa, 48,000 Mr RI (Sigma); RIIa,
56,000 Mr RII (Sigma). Lanes RI, and ROIL are from photoaffinity
labeling with [32P]8-N3-cAMP only; lanes 1-3, photoaffinity labeling
with [32P]8-N3-cAMP followed by immunoprecipitation with anti-RI,
or anti-RI1 antiserum. 8-Cl, 8-Cl-cAMP (5 uM); N6-benzyl, N6-
benzyl-cAMP (5 uM). Data in the table represent quantification by
densitometric scanning of autoradiograms. Data are expressed rel-
ative to levels in control cells unexposed to RIa antisense oligomer
and untreated with cAMP analog, which are set equal to one arbitrary
unit. Data represent an average ± SD of three experiments. Immu-
noprecipitation was with anti-RIa (A) or anti-Rllp3 (B) antisera.
and RIIh gene expression led to an abnormal cellular growth
regulation similar to that in those mutant cell lines (38) that
contain either deficient or defective regulatory subunits of
cAMP-dependent protein kinase and are no longer sensitive
to cAMP stimulus.
Our results demonstrated that cAMP transduces signals for
dual, either positive or negative, controls on cell prolifera-
tion, depending on the availability of RI, or REII receptor
Table 1. Modulation of differentiation markers in HL-60 cells by
RI, antisense oligodeoxynucleotide
Surface markers, % positive
Treatment Leu 15 Leu M3 My9
Control 10 2 100
RI, antisense 80 98 80
RI, antisense + RIIM antisense 11 2 100
RIIp antisense 13 3 100
RI, antisense + RII. antisense 85 100 80
Surface-antigens were analyzed by flow cytometry and monoclo-
nal antibodies (Leu 15, Leu M3, and My9) reactive with either
monocytic or myeloid cells. Approximately 2 x 104 cells were
analyzed for each sample, and cells were gated by using forward and
side scatter. Numbers represent the average values of three exper-
iments.
proteins. The RIa antisense oligodeoxynucleotide, which
suppressed RIa and enhanced RIIB expression, led to termi-
nal differentiation of HL-60 leukemia with no sign of cyto-
toxicity.
It is unlikely that free C increase in cells exposed to RIa
antisense oligodeoxynucleotide was responsible for the dif-
ferentiation because cells exposed to RIIB antisense or both
RI, and RIIB antisense oligodeoxynucleotides, conditions
that also would produce free C, continued to grow and
became refractory to cAMP stimulus. To directly verify this
we measured phosphotransferase activity in cells that are
exposed or unexposed to the antisense oligodeoxynucleo-
tides using Kemptide (22) as a substrate in the presence and
absence of a saturating concentration of cAMP and in the
presence and absence of the heat-stable protein kinase in-
hibitor (23). This method of assay gives accurate determina-
tion of the relative levels ofdissociated C and total C activity.
Cell extracts from untreated HL-60 cells exhibited a very low
level of dissociated C and were stimulated 36-fold by cAMP
(Table 2). This cAMP-stimulated activity was almost com-
pletely inhibited by the heat-stable protein kinase inhibitor
(Table 2), indicating that the total C activity measured was
cAMP-dependent protein kinase. In cells exposed to RIa
antisense, RIIB antisense, or RIa and Rh,3 antisense oligode-
oxynucleotides, the free C activity was not increased as
compared with unexposed control cells, although the total
cAMP-stimulated activity differed slightly (Table 2). These
results provide direct evidence that free C is not responsible
for the differentiation seen in HL-60 cells.
Overexpression of RIa cAMP receptor protein has also
been found in most human breast and colon primary carci-
nomas examined (39), suggesting an important in vivo role of
Table 2. Protein kinase activity in HL-60 cells
-cAMP +cAMP
Relative Relative Stimulation,
Treatment Activity* to control Activity* to control -fold
-PKI
Control 23.0 ± 6.6 1.0 837 ± 87 1.0 36
RIa antisense 22.9 ± 5.4 1.0 944 ± 18 1.1 41
RMIg antisense 22.8 ± 8.1 1.0 1028 ± 154 1.2 45
RIa and RMg antisense 24.3 ± 7.0 1.1 802 ± 36 1.0 33
+ PKI
Control 17.5 ± 8.7 1.0 37.0 ± 8.4 1.0 2.1
RIa antisense 25.0 ± 8.8 1.4 22.6 ± 8.8 0.6 0.9
RIIp antisense 24.0 ± 2.6 1.4 24.8 ± 3.9 0.7 1.0
RIa and ROIL antisense 19.0 ± 5.9 1.1 19.1 ± 8.2 0.5 1.0
Cells were exposed to 15 MM concentrations of RI,, RMIg, or to 15 uM each of both antisense oligodeoxynucleotide for
4 days (see Fig. 1A). Data represent an average ± SD of duplicate determinations from three identical experiments. PKI,
protein kinase inhibitor.
*pmol of phosphate transferred to kemptide per min/mg of protein.
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RIa cAMP receptor in tumor growth as well. However, the
precise role of RI, in cell proliferation is not yet known. RIa
may suppress RII production by titrating out C, or it may be
a transducer of mitogenic signals leading to cell proliferation.
Our results show that RI, antisense oligodeoxynucleotide
provides a useful genetic tool for studies on the role ofcAMP
receptor proteins in cell proliferation and differentiation and
contribute to another approach in the control of malignancy.
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